CC chemokine receptor 5 gene polymorphisms in beryllium disease

Area of Science:

• Immunogenetics
• Pulmonary Medicine
• Occupational Lung Diseases

Background:

• CC chemokine receptor 5 (CCR5) is expressed on type-1 T-helper cells, crucial in chronic beryllium disease (CBD) pathogenesis.
• CCR5 gene polymorphisms have been linked to sarcoidosis severity, prompting investigation into their role in CBD.

Purpose of the Study:

• To investigate the association between CCR5 gene polymorphisms and the development and progression of chronic beryllium disease (CBD).
• To determine if specific CCR5 genotypes or alleles correlate with pulmonary function decline or disease severity markers in CBD patients.

Main Methods:

• Genotyping of eight CCR5 polymorphisms in individuals with CBD, beryllium sensitization (BeS), and healthy controls using PCR.
• Analysis of pulmonary function tests (spirometry) and bronchoalveolar lavage (BAL) findings in relation to CCR5 genotypes.

Main Results:

• No significant differences in genotype or allele frequencies were observed between CBD, BeS, and control groups.
• In CBD patients, the CCR5 -3458 T/T genotype was associated with a decline in FEV1 and FVC, while the -5663 adenine allele correlated with increased alveolar-arterial oxygen difference.
• Increased BAL lymphocyte counts in the combined CBD and BeS group were linked to the CCR5 -2459 G/-2135 T genotype.

Conclusions:

• This study provides the first evidence that CCR5 polymorphisms are associated with progressive pulmonary function decline in chronic beryllium disease (CBD).
• CCR5 gene variations may influence the progression of lung disease in individuals exposed to beryllium.
• Further research is warranted to elucidate the specific mechanisms by which CCR5 polymorphisms impact CBD progression.